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tein concentrations was the same in infants with gestational 
ages  ! 29 weeks and in those with gestational ages  6 29 
weeks.  Conclusions: Our data suggest that the higher renal 
Epo excretion in more immature infants may be attributed 
to a higher glomerular filtration leakage due to the lower 
maturation of the kidneys and argue against saturation ki-
netics after multiple doses of 3,000 U/kg rEpo. This informa-
tion should be considered in future trials on the use of rEpo 
for neuroprotection in neonates. 
 Copyright © 2012 S. Karger AG, Basel 
 Introduction 
 Animal models of neonatal brain injury have indicat-
ed significant neuroprotective effects of high-dose re-
combinant human erythropoietin (rEpo) treatment, 
leading to the first clinical trials in (near-) term neonates 
with hypoxic-ischemic encephalopathy (HIE) and in very 
preterm neonates at high risk of intraventricular hemor-
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 Abstract 
 Background:  High-dose recombinant human erythropoie-
tin (rEpo) has first been administered in clinical trials for neu-
roprotection in very preterm neonates at high risk of brain 
injury and in (near-) term neonates with hypoxic-ischemic 
encephalopathy. However, recent trials in adults raised con-
cerns about the safety of high-dose rEpo for neuro- and car-
dioprotection.  Objectives: To evaluate the putative accumu-
lation or renal leakage of Epo as a function of developmental 
stage after repetitive early short-term infusion of high-dose 
rEpo (3  ! 3,000 U/kg within 42 h after birth; NCT00413946) 
for neuroprotection in very preterm infants.  Methods: Epo 
concentrations were measured using the ELISA technique in 
the first two consecutive urine specimens after each rEpo 
infusion.  Results: Renal Epo excretion was significantly high-
er in preterm infants with gestational ages  ! 29 weeks than 
in more mature infants and reached up to 23% of the admin-
istered rEpo within 8 h after each infusion. The urinary Epo 
concentration did not increase after three repetitive infu-
sions of high-dose rEpo. The ratio of urinary Epo to total pro-
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rhage or periventricular leukomalacia  [1–4] . Important 
questions on the dosing strategy (optimal timing, dosage, 
route and repetitive infusion) remain open, and long-
term follow-up analysis on secondary outcome measures 
needs to be considered. Although both trials using early 
high-dose rEpo in very preterm infants did not show any 
significant differences in safety parameters or any toxic 
side effects as compared with the placebo control groups 
 [1, 2] , concerns regarding adverse effects associated with 
high-dose rEpo in adults with stroke  [5] , cardiovascular 
disorders  [6] , renal failure  [7] , or cancer  [8] prompted the 
FDA to issue a temporary hold on clinical trials on tissue-
protective effects of high-dose rEpo  [9] .
 Among the studies investigating early high-dose rEpo 
for neuroprotection in preterm infants, the US phase II 
trial on ‘High-Dose Erythropoietin in Extremely Pre-
mature Infants to Prevent/Attenuate Brain Injury’ 
(NCT00589953) was registered in 2007, but placed on 
FDA hold until 2010, and has still not been initiated yet. 
A novel US phase II/III ‘Trial of Erythropoietin Neu-
roprotection in Extremely Preterm Infants (PENUT; 
NCT013778273) is supposed to start recruitment in July 
2012. The previous US ‘Phase I/II trial of high-dose rEpo 
in extremely low birth weight infants’ (IND12656) pro-
vided data on Epo plasma levels after early high-dose in-
travenous rEpo. Considering the ongoing discussion 
about the safety of rEpo in neonates  [10–13] , we evaluated 
the putative accumulation or renal leakage of Epo as a 
function of developmental stage following repetitive ear-
ly short-term infusion of high-dose rEpo for neuropro-
tection in very preterm infants included in the ongoing 
Swiss phase II trial (NCT00413946).
 Methods 
 269 urine specimens (rEpo n = 154; placebo n = 115) were ob-
tained from 75 neonates (rEpo n = 42; placebo n = 33) included in 
this randomized, controlled double-blind, multicenter trial on 
the use of high-dose rEpo (epoetin-beta, Hoffmann-La Roche) for 
neuroprotection in very preterm infants (NCT00413946). Urine 
specimens were collected from all consecutive patients recruited 
at the Zurich study center from January 2006 to October 2009. In 
3 patients, we were unable to collect at least two urine specimens, 
which was the only putative reason for excluding patients from 
the subanalysis. These patients did not suffer from HIE. Their 
demographic data are summarized in  table 1 . Frequencies of traits 
were compared by odds ratios with 95% confidence intervals. 
Continuous measurements that followed a normal distribution 
are summarized as means and standard deviation plus 95% con-
fidence intervals for the difference between means. The CRIB 
score is reported as medians and interquartile ranges  [1] . Patients 
were treated either with 3,000 U epoetin-beta per kilogram body 
weight, administered as a short-term infusion over a period of 10 
min at 1–3, 12–18 and 36–42 h after birth or with an equivalent 
volume of 0.9% NaCl. The first two consecutive urine specimens 
after each rEpo infusion were collected using polyethylene tubes 
in male and sterile gloves in female infants. Corresponding plas-
ma/serum or cerebrospinal fluid specimens were not taken to 
avoid unnecessary blood loss or lumbar taps. Epo concentrations 
Table 1. Demographic data
Demographic data rEpo Placebo Difference1 Odds ratio1 p
(n = 42) (n = 33) value
Girls, n 16 (38%) 9 (27%) 1.641 (0.611–4.404) 0.32
Mean gestational age 8 SD, weeks + days 29 1/781 6/7 29 2/781 5/7 0 2/7 (–0 4/7 to 1 4/7) 0.56
Mean birth weight 8 SD, g 1,2118327 1,2418341 30 (–184 to 124) 0.70
Mean z-score 8 SD 0.0680.78 0.00580.93 0.06 (–0.33 to 0.45) 0.76
Mean birth head circumference 8 SD, cm 26.682.0 27.482.3 –0.7 (–1.7 to 2.1) 0.12
Mean z-score 8 SD –0.1080.61 0.0980.85 –0.20 (–0.54 to 0.13) 0.23
Chorioamnionitis, n 15 (36%) 8 (24%) 1.736 (0.628–4.795) 0.28
Antenatal steroids, n 32 (76%) 25 (75%) 1.024 (0.352–2.975) 0.96
Cesarean section, n 36 (85%) 33 (100%) 0.083 (0.004–1.545) 0.09
Mean pH umbilical artery 8 SD 7.31 (0.09%) 7.35 (0.07%) –0.02 (–0.06 to 0.01) 0.26
Mean maximum negative base excess 8 SD –5.1 (2.9%) –4.0 (2.9%) –1.1 (–2.4 to 0.3) 0.12
Apgar score at 5 min ≤5, n 8 (19%) 6 (18%) 1.058 (0.327–3.42) 0.97
Median CRIB score2 2 (4–1) 1 (4–1) 1
Catecholamine treatment, n 4 (10%) 2 (6%) 1.631 (0.28–9.506) 0.58
Mechanical ventilation, n 13 (31%) 11 (33%) 0.896 (0.338–2.378) 0.82
1 Figures shown in parentheses are 95% confidence intervals. 2 Figures shown in parentheses are interquartile ranges.
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were determined in duplicate using the Quantikine Human Epo 
Immunoassay (R&D Systems), with a lower detection limit of 2.5 
mU/ml; the intra-assay variability was  ! 2%. Total urinary protein 
concentrations were determined using the Microassay Protocol of 
the Quick Start TM Bradford Protein Assay (Bio-Rad Laboratories) 
according to the manufacturer’s instructions. The study was 
blinded in that only the study pharmacist had access to the pa-
tients’ allocation to the rEpo or placebo group. After measuring 
the urinary Epo concentrations, the anonymous data were sorted 
into the rEpo or placebo group by the pharmacist. All investiga-
tors remained strictly blinded to this allocation in order not to 
prejudice any aspect of long-term follow-up examination. As to 
the renal development and functional adaptation of the kidneys 
 [14–16] , patients were allocated to two groups according to their 
gestational age at birth: group 1: 26 0/7–28 6/7 weeks (rEpo n = 21; 
placebo n = 14); group 2: 29 0/7–31 6/7 (rEpo n = 21; placebo n = 
19). For statistical analysis, the Mann-Whitney U test (two-sided) 
or the ANOVA were applied as indicated. A p value  ! 0.05 was 
considered to be significant.
 Results 
 Epo was undetectable in 86.2% of the urine samples of 
the placebo group. In the remaining Epo-positive sam-
ples, the Epo concentration ranged between 2.5 and 18.1 
mU/ml. In the rEpo group, 98.7% of urine samples tested 
positive for Epo. The urinary Epo concentrations (me-
dian 3.930; range  ! 2.5–48.940 mU/ml) in the rEpo group 
were significantly higher (p  ! 0.001) than in the placebo 
group. Infants with gestational ages  ! 29 weeks had sig-
nificantly higher urinary Epo concentrations than more 
mature infants (p = 0.03). In both subgroups, the urinary 
Epo concentrations did not significantly differ in the first 
and the second urine sample taken after each of the three 
repetitive rEpo infusions. Nor was there a significant 
change in urinary Epo concentrations after the first, sec-
ond or third infusion of high-dose rEpo ( fig. 1 a). Notably, 
outlying or extreme values were not found to be depen-
dent on any of the analyzed parameters, including the 
finding of oligohydramnios prior to birth, presence of 
chorioamnionitis, or treatment with antibiotics or cate-
cholamines. None of the patients were treated with indo-
methacin prior to the third infusion of rEpo. The ratios 
between urinary Epo and total urinary protein concen-
trations were almost equal in both subgroups; this was 
also the case after repetitive rEpo infusions ( fig. 1 b). Lon-
gitudinal analysis of individual patients indicated no 
changes in the peak and trough concentrations after the 
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 Fig. 1. Urinary Epo concentrations ( a ) and ratio of urinary Epo to urinary total protein concentrations ( b ) in 
very preterm infants, who received 3,000 U epoetin-beta per kilogram body weight as short-term infusion. Pa-
tients were allocated to two groups according to gestational ages  ! 29 or  6 29 weeks. Numbers represent the 
number of urine specimens investigated. Statistical analysis was performed using ANOVA. 
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repetitive rEpo infusions ( fig. 2 ). The patients shown in 
 figure 2 have been selected for the graphic presentation 
since collection of two consecutive urine specimens after 
each rEpo infusion could be successfully completed only 
in these 6 patients.
 In infants with gestational ages  ! 29 weeks treated for 
neuroprotection with a short-term infusion of 3,000 U 
rEpo per kilogram body weight, up to 23% (median 2.8%) 
of rEpo was secreted in the urine within the first 8 h. This 
urinary Epo excretion reached only up to 9.4% (median 
1.2%) in infants with gestational ages  6 29 weeks.
 Discussion 
 Our study provides the first data on urinary Epo con-
centrations in preterm infants treated with high-dose 
rEpo for neuroprotection. Compared with the placebo 
group, significantly higher urinary Epo concentrations 
were detected in the rEpo group. In the rEpo group, uri-
nary Epo concentrations were significantly higher in pre-
term infants born at gestational ages  ! 29 weeks com-
pared with more mature infants (p  ! 0.05;  fig. 1 a). This 
finding parallels of higher mean plasma creatinine con-
centrations within the first 48 h and with a lower plasma 
creatinine clearance (as a measure of the glomerular fil-
tration rate) in very immature ( ! 29 weeks of gestation) 
versus more mature infants  [15, 16] . Due to these funda-
mental developmental changes and variable maternal/
perinatal factors, the amount of early Epo excretion can-
not be directly correlated with renal function based on 
plasma creatinine levels, or the glomerular filtration rate 
within the first 48 h after birth. However, equal ratios be-
tween urinary Epo and total urinary protein concentra-
tions ( fig. 1 b) indicate that higher Epo excretion in the 
more immature infants may result from a greater protein 
leakage in glomerular filtration.
 Interestingly, we were also able to measure low, but 
detectable Epo concentrations (max. 18.1 mU/ml) in a few 
urine samples of the placebo group (13.8%). This observa-
tion may be explained by the fact that fetal distress (ane-
mia, hypoxia, preeclampsia, maternal type 1 diabetes) in-
duces sufficient endogenous Epo production, which leads 
to detectable or even high Epo concentrations in the am-
niotic fluid  [17] . Importantly, baseline urinary Epo con-
centrations in healthy adults also range between 9.3 and 
23 mU/ml  [18] .
 Nonlinear pharmacokinetics of early high-dose rEpo 
for neuroprotection in very premature infants was deter-
mined based on repetitive analysis of plasma Epo concen-
trations in very preterm infants in the US phase I/II clin-
ical trial  [2] , indicating a decreasing clearance from the 
lowest dose (17.3 ml/kg/h; rEpo 500 U/kg) to the highest 
dose (8.2 ml/kg/h; rEpo 2,500 U/kg). For doses up to 
2,500 U/kg/day, administered on 3 consecutive days, 
peak and trough concentrations did not significantly 
change after the second dose  [2] . Our data parallel these 
results by showing similar high urinary Epo concentra-
tions after the first, second and third high-dose rEpo in-
fusions, and thus support the conclusion that there is no 
evidence for rEpo accumulation after multiple doses of 
3,000 U/kg rEpo administered to very preterm infants; 
using a drug with nonlinear pharmacokinetics would 
otherwise be an important issue.
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 Fig. 2. Longitudinal analysis of urinary 
Epo concentrations in 6 infants with ges-
tational ages  ! 29 weeks at birth, treated 
with short-term infusions of 3,000 U epo-
etin-beta per kilogram body weight. Cir-
cles indicate urinary Epo concentrations 
in two consecutive specimens taken after 
the first, second and third infusion of 
rEpo. The arrows, colored to follow up 
each individual patient, indicate the time 
point of the second and third rEpo infu-
sion. The first dose was given within 3 h 
after birth. For colors, see online version. 
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 Of note, the excreted Epo in relation to the infused 
rEpo dose decreased from up to 23% within the first 8 h 
after the first short-term infusion of rEpo in infants with 
gestational ages  ! 29 weeks to a maximum of 9.4% in in-
fants with gestational ages  6 29 weeks. A similar amount 
of Epo excreted in the urine (3–10%) has been detected in 
healthy adults who received low-dose rEpo (200 U/kg/day 
s.c.)  [18] . In preterm infants treated with a low dose of 250 
U/kg rEpo for anemia of prematurity, up to 2.8% of Epo 
was excreted in the urine within the first 8 h after the first 
intravenous administration  [19] . These data argue against 
saturation kinetics. Rather, they suggest the conclusion 
that a higher Epo excretion in the more immature infants 
is caused by the lower maturation of their kidneys.
 Regarding the efficacy of early high-dose Epo, the low-
er renal Epo excretion in infants with gestational ages 
 1 29 weeks may be important.
 Both published trials  [3, 4] and the ongoing, but 
not active trials (NCT00719407; NCT00513240, 
NCT00491413) on the effects of rEpo in (near-) term in-
fants suffering from HIE follow different conceptual 
strategies regarding the timing, dosage, route and repeti-
tion of rEpo administration. Since these infants frequent-
ly suffer from oliguria or anuria during the first days after 
birth, we recommend the assay of urinary (and if possible 
plasma) Epo concentrations and creatinine clearance in 
the ongoing trials in order to gain insight into the phar-
macokinetics of early high-dose rEpo treatment for neu-
roprotection in HIE. Initial accumulation or later in-
creased leakage may contribute to the finding that rEpo 
improved the long-term outcome only in infants with 
moderate, but not with severe, HIE  [3] .
 In an approach that combines therapeutic hypother-
mia with rEpo or darbepoietin (a highly glycosylated 
Epo derivate) treatment for neuroprotection after HIE 
(NCT01471015), it should be considered that hypother-
mia may further reduce the glomerular filtration rate  [20, 
21] and also modify renal rEpo protein leakage or accu-
mulation. Notably, in adults with out-of-hospital cardiac 
arrest, early high-dose rEpo plus hypothermia resulted in 
a higher incidence of thrombocytosis as a putative side 
effect of rEpo  [22] .
 In conclusion, the difference in glomerular filtration 
leakage of rEpo should be considered as a variable in the 
saturation kinetics of high-dose rEpo in very immature 
premature infants and thus as a putative factor influenc-
ing the neuroprotective benefit of rEpo.
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